Last updated on March 2018

International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis


Brief description of study

BCD-085-5 is an International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-5 trial patients with active ankylosing spondylitis will receive 120 mg of BCD-085 subcutaneously every other week or placebo up to Week 16. Starting from week 16 all patients will receive BCD-085. Efficacy, PK and safety parameters will be evaluated.

Clinical Study Identifier: NCT03447704

Contact Investigators or Research Sites near you

Start Over

Ekaterina Chernyaeva

Non-governmental Healthcare Institution "Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways"
Chelyabinsk, Russian Federation
  Connect »

Ekaterina Chernyaeva

Chelyabinsk Regional Clinical hospital
Chelyabinsk, Russian Federation
  Connect »

Ekaterina Chernyaeva

Kazan State Medical University
Kazan, Russian Federation
  Connect »

Ekaterina Chernyaeva

State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University
Moscow, Russian Federation
  Connect »

Ekaterina Chernyaeva

Omsk Regional Clinical Hospital
Omsk, Russian Federation
  Connect »

Ekaterina Chernyaeva

LLC BioEk
Saint-Petersburg, Russian Federation
  Connect »

Ekaterina Chernyaeva

North-Western State Medical University n.a. I.I.Mechnikov
St.Petersburg, Russian Federation
  Connect »